185517-21-9

Arundic acid is an inhibitor of astrocyte activation. It reduces increases in brain glial fibrillary acid protein (GFAP) and S100β levels, markers of astrocyte activation, in a rat model of permanent focal ischemia induced by middle cerebral artery occlusion when administered at a dose of 10 mg/kg. Arundic acid (3 and 10 mg/kg) decreases the number of TUNEL-positive neurons, reduces infarct size, and improves motor performance in the rotarod test in the same model. It also reduces descent time and time to turn in a pole test, indicating reversal of motor deficits, in a mouse model of MPTP-induced Parkinson''s disease when administered at a dose of 30 mg/kg.

Clear Colorless Oil

An astrocyte modulating agent, in acute ischemic stroke.

Store at -20°C

[1] N. TATEISHI. Astrocytic Activation and Delayed Infarct Expansion after Permanent Focal Ischemia in Rats. Part II: Suppression of Astrocytic Activation by a Novel Agent (R)-(?)-2-propyloctanoic acid (ONO-2506) Leads to Mitigation of Delayed Infarct Expansion and Early Improvement of Neurologic Deficits[J]. Journal of Cerebral Blood Flow & Metabolism, 2002, 26 1: 723-734. DOI: 10.1097/00004647-200206000-00011
[2] HIROYUKI KATO . Arundic acid, an astrocyte-modulating agent, protects dopaminergic neurons against MPTP neurotoxicity in mice[J]. Brain Research, 2004, 1030 1: Pages 66-73. DOI: 10.1016/j.brainres.2004.09.046